Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | The University of Manchester |
| Country | United Kingdom |
| Start Date | Oct 01, 2024 |
| End Date | Sep 30, 2029 |
| Duration | 1,825 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 101165606 |
Despite unprecedented clinical success, T cell-based immunotherapies present significant heterogeneity in response rates, often attributed to dampened activation and limited tumour infiltration of CD8+ T cells.
Studies in mice and humans have shown that gut commensals can modulate anti-cancer immune responses dictating the efficacy of immunotherapy, but have failed to identify species that are consistently associated with improved patient prognosis.
I recently made a breakthrough in our efforts to understand the host determinants that define microbiome-dependent cancer immunity.
I discovered that a single micronutrient, vitamin D (vitD), enhances the ability of the gut microbiome to induce potent T cell-mediated immunity to cancer, dictating immunotherapy success in pre-clinical models.
Unlike any other study, I found that vitD modulates the function of the microbiome without significantly affecting its composition, diverging from a species-centric view of the microbiome to focusing on key host-microbiome interactions regulated by nutrient availability.MICROBIOGUARD attempts to systematically dissect the multidirectional gut-immune-cancer axis.
We first address a key question in the field: what defines a good microbiome that promotes immunity to cancer?
Aim 1 of this proposal will dissect the mechanisms by which vitD transforms the function of the gut microbiome with a focus on identification of microbial-derived bioactive molecules.
We will then assess how these altered microbial functions interact with host cells bidirectionally to shape anti-cancer immunity (Aims 1/2). We will broaden our findings and determine how vitD-microbiome-immune interactions impact cancer development. Finally, we will investigate if vitD enables human microbiome to augment immunotherapy response (Aim 3).
Collectively, MICROBIOGUARD provides an unmatched opportunity to identify non-redundant microbiome-immune checkpoints that can be targeted to overcome immunotherapy resistance.
The University of Manchester
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant